Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed newly diagnosed unresectable glioblastoma multiforme (GBM), recurrent GBM, or recurrent anaplastic astrocytoma (AA)
• •MRI scan documenting gadolinium enhanced tumor volume of at least 5 cm3, but no greater than 60 cm\^3
• •* Recurrent GBM and AA must be documented by MRI after the most recent treatment and before any planned surgical debulking
• •At least 5 days since prior surgical debulking
• •No planned resection of newly diagnosed GBM before or during study
• •No bilateral noncontiguous gadolinium enhancing tumors
• •No satellite lesions greater than 1.5 cm from anticipated location of interstitial catheter tip
• •No more than 2 satellite lesions
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •Karnofsky 60-100%
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Platelet count at least 100,000/mm\^3
• •Absolute neutrophil count at least 1,500/mm\^3
• •WBC at least 3,000/mm\^3
• •Hepatic:
• •Hepatitis B surface antigen negative
• •Bilirubin no greater than 2.5 times upper limit of normal (ULN)
• •SGOT and SGPT no greater than 3 times ULN
• •Alkaline phosphatase no greater than 3 times ULN
• •Lactic dehydrogenase no greater than 3 times ULN
• •Prothrombin time no greater than 1.5 times ULN
• •Renal:
• •Creatinine clearance at least 50 mL/min
• •Cardiovascular:
• •No significant unstable cardiovascular disease
• •No New York Heart Association class III/IV heart disease
• •No evidence of myocardial infarction within the past 3 months
• •Other:
• •Not pregnant
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •Human antichimeric antibody (HACA) titer no greater than 48 ng/mL
• •No anatomical or physiological considerations that would preclude study participation
• •No active autoimmune disease, active infection, or traumatic injury requiring treatment
• •HIV negative
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •At least 4 weeks since prior intravenous chemotherapy or Gliadel wafers
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •At least 8 weeks since prior external beam or gamma knife radiotherapy
• •Surgery:
• •See Disease Characteristics
• •Other:
• •At least 30 days since prior investigational treatment